Drugs / COLAL-PRED
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00676832 | May 2008 → Oct 2009 | ulcerative colitis | Prometheus Laboratories | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COLAL-PRED | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00676832 ↗ |
| Route | Oral | “A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.” NCT00676832 ↗ |